Search

Displaying results 6451 - 6460 of 8171 in total
  1. Drug

    SYNB1891

    go.drugbank.com/drugs/DB17541
    Investigational

    SYNB1891 is a live, modified strain of the probiotic _Escherichia coli_ Nissle engineered to produce cyclic di-AMP (CDA), a stimulator of the STING (STimulator of INterferon Genes) pathway.

  2. Drug

    Nifurizone

    go.drugbank.com/drugs/DB19694
    Experimental

    Nifurizone has a monoisotopic molecular weight of 307.09 Da.

  3. Drug

    Gamcemetinib

    go.drugbank.com/drugs/DB21624
    Investigational

    Gamcemetinib has a monoisotopic molecular weight of 469.1 Da.

  4. Drug

    Nifurethazone

    go.drugbank.com/drugs/DB20112
    Experimental

    Nifurethazone has a monoisotopic molecular weight of 269.11 Da.

  5. Drug

    Aniline

    go.drugbank.com/drugs/DB06728
    Investigational

    Aniline, phenylamine or aminobenzene is an organic compound with the formula C6H5NH2. Consisting of an amine attached to a benzene ring, aniline is the prototypical aromatic amine.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2E1 Substrates
  6. Drug

    Sisunatovir

    go.drugbank.com/drugs/DB15674
    Investigational

    Sisunatovir is under investigation in clinical trial NCT04267822 (Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV).

  7. Drug

    Apazunersen

    go.drugbank.com/drugs/DB16981
    Investigational

    Apazunersen is an antisense oligonucleotide designed to target and inhibit the expression of UBE3A-AS. It is being investigated for the treatment of Angelman Syndrome.[L46772]

  8. Drug

    GS-9191

    go.drugbank.com/drugs/DB15084
    Investigational

    GS-9191 is under investigation in clinical trial NCT00499967 (Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts).

    Categories: P-glycoprotein inhibitors
  9. Drug

    AZD2315

    go.drugbank.com/drugs/DB06540
    Experimental

    The drug AZD2315, an immunosuppressant developed by AstraZeneca, was in Phase 1 clinical trials for the treatment of rheumatoid arthritis but was discontinued during this phase

  10. Drug

    Apitegromab

    go.drugbank.com/drugs/DB16096
    Investigational

    Apitegromab is under investigation in clinical trial NCT03921528 (An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy).